Financial Performance - The company's operating revenue for Q1 2023 was ¥119,423,435.11, a decrease of 0.85% compared to ¥120,451,245.21 in the same period last year[4] - The net profit attributable to shareholders was ¥4,024,418.08, representing a significant decline of 69.15% from ¥13,044,337.80 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥115,039.00, down 99.09% from ¥12,583,964.03 in the previous year[4] - The company’s basic and diluted earnings per share were both ¥0.03, down 72.73% from ¥0.11 in the same period last year[4] - Net profit for Q1 2023 was CNY 3,651,134.29, down 71.5% from CNY 12,776,354.19 in Q1 2022[20] - Total operating costs increased to CNY 120,171,920.93, up 10.57% from CNY 108,873,562.70 in the previous year[19] Cash Flow - The net cash flow from operating activities was -¥57,394,913.52, worsening by 56.99% compared to -¥36,560,040.95 in the same period last year[4] - The net cash flow from operating activities decreased by 56.99% to -57,394,913.52 RMB due to reduced cash received from sales and increased cash paid for purchases[14] - The company reported a net cash outflow from operating activities of CNY -57,394,913.52, compared to CNY -36,560,040.95 in Q1 2022[21] - The cash inflow from operating activities totaled CNY 120,839,809.00, down from CNY 134,908,853.94 in Q1 2022[21] - The net cash flow from investing activities increased by 125.81% to -148,163,433.78 RMB primarily due to cash used for fixed asset construction related to fundraising projects[14] - The net cash flow from investment activities was -148,163,433.78 CNY, indicating a significant outflow compared to the previous period's outflow of -65,614,398.87 CNY[22] - The total cash inflow from financing activities was 130,377,770.11 CNY, while the cash outflow was 123,527,591.55 CNY, resulting in a net cash flow of 6,850,178.56 CNY[22] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥2,076,908,041.96, a slight increase of 0.42% from ¥2,068,317,317.70 at the end of the previous year[5] - The total liabilities increased to CNY 1,092,116,167.07, compared to CNY 1,087,176,743.47 in the previous year[20] - Total current assets decreased from 1,213,731,540.24 RMB to 1,063,291,961.48 RMB, with cash and cash equivalents dropping significantly[17] - Short-term borrowings decreased from 321,630,876.40 RMB to 200,000,000.00 RMB, indicating a reduction in debt levels[17] - Long-term borrowings increased from 158,120,000.00 RMB to 288,497,770.11 RMB, suggesting a shift towards long-term financing[17] Shareholder Information - The company reported a total of 16,351 common shareholders at the end of the reporting period[14] - The top shareholder, Xi Zubin, holds 31.72% of the shares, amounting to 36,567,000 shares[14] Government Support and Other Income - The company received government subsidies amounting to ¥4,600,062.17 during the reporting period[6] - The company recorded an investment income of CNY 92,910.39, compared to a loss of CNY 2,053.21 in the previous year[20] Research and Development - R&D expenses rose to CNY 10,545,515.62, an increase of 18.6% from CNY 8,891,743.44 in the same period last year[20] Other Observations - The report was not audited, which may affect the reliability of the financial data presented[23] - The company experienced a foreign exchange impact of 18,738.78 CNY on cash and cash equivalents[22] - The cash outflow for the acquisition of fixed assets and intangible assets was 133,205,299.96 CNY, significantly higher than the previous period[22] - The company has not disclosed any new product developments or market expansion strategies in the provided report[22]

Financial Performance - The company's operating revenue for Q1 2023 was ¥119,423,435.11, a decrease of 0.85% compared to ¥120,451,245.21 in the same period last year[4] - Net profit attributable to shareholders was ¥4,024,418.08, down 69.15% from ¥13,044,337.80 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥115,039.00, a significant decline of 99.09% compared to ¥12,583,964.03 in the previous year[4] - The basic earnings per share decreased by 72.73% to ¥0.03 from ¥0.11 in the same period last year[4] - Net profit for Q1 2023 was CNY 3,651,134.29, down 71.5% from CNY 12,776,354.19 in Q1 2022[20] Cash Flow - The net cash flow from operating activities was -¥57,394,913.52, worsening by 56.99% from -¥36,560,040.95 in the same period last year[4] - The net cash flow from operating activities decreased by 56.99% to -57,394,913.52 RMB due to reduced cash received from sales and increased cash paid for purchases[14] - The company reported a net cash outflow from operating activities of CNY -57,394,913.52, compared to CNY -36,560,040.95 in Q1 2022[21] - The net cash flow from investing activities increased by 125.81% to -148,163,433.78 RMB primarily due to cash spent on fixed asset construction for fundraising projects[14] - The net cash flow from financing activities decreased by 93.93% to 6,850,178.56 RMB, attributed to reduced minority shareholder investments and increased loan repayments[14] - The net cash increase for the period was -198,689,429.96 CNY, reflecting a challenging cash flow situation[22] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,076,908,041.96, an increase of 56.07% from ¥1,330,717,680.91 at the end of the previous year[5] - Total current assets decreased from 1,213,731,540.24 RMB to 1,063,291,961.48 RMB, with cash and cash equivalents dropping significantly[17] - The total liabilities increased to CNY 1,092,116,167.07, compared to CNY 1,087,176,743.47 in the previous year[20] - Short-term borrowings decreased from 321,630,876.40 RMB to 200,000,000.00 RMB, indicating a reduction in debt levels[17] - Long-term borrowings increased from 158,120,000.00 RMB to 288,497,770.11 RMB, suggesting a shift towards long-term financing[17] Shareholder Information - Shareholders' equity attributable to the parent company was ¥932,094,662.82, up 13.66% from ¥820,097,355.16 at the end of the previous year[5] - The number of common shareholders at the end of the reporting period was 16,351, with the largest shareholder holding 31.72% of the shares[14] - The total equity attributable to shareholders of the parent company was CNY 932,094,662.82, slightly up from CNY 928,070,078.38 in Q1 2022[20] Operational Costs and Expenses - Total operating costs increased to CNY 120,171,920.93, up 10.57% from CNY 108,873,562.70 in the previous year[19] - R&D expenses rose to CNY 10,545,515.62, an increase of 18.6% compared to CNY 8,891,743.44 in the same period last year[20] - The company reported an increase in financial expenses to CNY 2,868,072.48, compared to CNY 3,134,227.30 in Q1 2022[20] Other Financial Metrics - The weighted average return on equity fell to 0.43%, down 1.17% from 1.60% in the previous year[4] - Cash and cash equivalents decreased by 36.45% to ¥278,607,213.55 from ¥438,417,938.21 at the beginning of the year, primarily due to cash outflows for fixed asset purchases[9] - The company reported a significant increase in contract liabilities by 278.32%, reaching ¥2,104,208.06, compared to ¥556,201.33 at the beginning of the year[9] - The company reported a significant increase in accounts receivable from 172,850,260.34 RMB to 192,483,506.34 RMB, indicating potential cash flow issues[16] Audit and Reporting - The company did not conduct an audit for the first quarter report[23] - The cash flow from operating activities was not detailed in the provided data, indicating a potential area for further analysis[22]

Financial Performance - The company's operating revenue for 2022 was ¥604,571,473.19, an increase of 2.32% compared to ¥590,885,338.44 in 2021[26]. - The net profit attributable to shareholders for 2022 was ¥40,187,745.43, a decrease of 48.69% from ¥78,330,635.77 in the previous year[26]. - The net profit after deducting non-recurring gains and losses was ¥36,738,609.57, down 30.07% from ¥52,534,956.25 in 2021[26]. - The net cash flow from operating activities was negative at -¥24,036,809.43, a decline of 141.44% compared to ¥58,004,300.45 in 2021[26]. - The total assets at the end of 2022 reached ¥2,068,317,317.70, representing a 70.76% increase from ¥1,211,243,283.36 at the end of 2021[26]. - The net assets attributable to shareholders increased by 14.99% to ¥928,070,078.38 from ¥807,053,017.36 in 2021[26]. - The basic earnings per share for 2022 was ¥0.3486, a decrease of 53.00% from ¥0.7417 in the previous year[26]. - The weighted average return on net assets was 4.91%, down 6.23% from 11.14% in 2021[26]. - The company reported a quarterly revenue of ¥178,476,491.30 in Q3 2022, which was the highest among the four quarters[28]. - The net profit attributable to shareholders in Q4 2022 dropped significantly to ¥270,289.39, indicating a sharp decline in profitability[28]. - The company reported a net profit of 3,449,135.86 yuan for the year 2022, a decrease from 25,795,679.52 yuan in 2021, reflecting a significant decline of approximately 86.7%[32]. Investment and Capital Management - The company will not distribute cash dividends, issue bonus shares, or increase capital using reserves[13]. - The company has conducted thorough research and analysis on the feasibility of its fundraising projects, considering various factors to ensure future profitability[11]. - The total amount of funds raised by the company in 2021 through its initial public offering (IPO) was 194.18 million yuan, with 120.97 million yuan utilized in 2021 and 74.77 million yuan utilized by the end of 2022[82]. - In 2022, the company raised 373.22 million yuan through convertible bonds, with 354.10 million yuan utilized during the year, leaving a balance of 19.17 million yuan as of December 31, 2022[82]. - The total amount of funds raised by the company from both the IPO and convertible bonds reached 567.41 million yuan, with 428.88 million yuan utilized by the end of 2022[82]. - The company has committed to invest 600 million yuan in the production project of progesterone and intermediates, with 192.15 million yuan already invested, achieving 100.81% of the planned progress[84]. - The company plans to achieve an annual production capacity of 800 tons of BA (diol) and 200 tons of progesterone by 2023, reaching 40% of the target capacity[84]. Research and Development - The company plans to enhance its research and development capabilities by utilizing provincial recognized enterprise technology centers and key laboratories to explore products with market potential and technical barriers[7]. - The company acknowledges the high investment and long cycle associated with product research and development, which carries inherent uncertainties[7]. - The company has established R&D centers in Wuhan and Hangzhou to focus on molecular biology, enzyme engineering, fermentation engineering, and chemical synthesis, aiming to enhance innovation capabilities[36]. - Research and development expenses rose by 21.61% to CNY 45,147,487.65, primarily due to the operational commencement of three subsidiaries and increased staffing[62]. - The R&D investment as a percentage of operating revenue increased to 7.47% in 2022 from 6.28% in 2021, indicating a stronger focus on innovation[66]. - The number of R&D personnel with master's degrees increased from 4 in 2021 to 20 in 2022, marking a 400% growth[66]. - The company is actively developing new products in the raw material drug product chain, with several projects in various stages of development and international certification[65]. Market Position and Strategy - The company is the largest domestic supplier of steroid drug starting materials and has a complete product line covering steroid hormone intermediates, enhancing its competitive edge in the market[36]. - The global steroid hormone drug market has been growing at a rate of over 10% annually, indicating strong demand for steroid hormone intermediates and raw materials[35]. - The company is focusing on high-end steroid drug raw materials and formulations as part of its strategic planning to enhance market positioning[36]. - The company is actively expanding its production capacity through ongoing projects, aiming to enhance its market share and overall profitability[48]. - The company has established good cooperative relationships with major domestic and international clients, including Tianyao Co., Xianju Pharmaceutical, and others[41]. - The company is committed to improving production efficiency and reducing costs through the use of biocatalysis technology[49]. Environmental and Safety Compliance - The company emphasizes the importance of adhering to environmental policies and regulations to prevent potential safety and environmental risks[9]. - The company has implemented a comprehensive safety and environmental management system to enhance operational quality and ensure compliance[49]. - The company follows multiple environmental protection laws and standards, including the Environmental Protection Law of the People's Republic of China[162]. - The company holds a valid pollutant discharge permit until December 29, 2025[163]. - The company has established a strict independent hazardous waste storage area, ensuring proper collection and transfer of hazardous waste according to regulations[165]. - The company conducts daily sampling and analysis of wastewater treatment units, with online monitoring devices set up at discharge points to measure CODcr, pH, and flow every 2 hours[168]. - The company’s wastewater discharge meets the standards, with specific monitoring for pollutants like ammonia nitrogen and total phosphorus[169]. Governance and Management - The company maintains complete independence in its main business operations, which include the research, production, and sales of steroid drug raw materials[120]. - The company's assets are entirely independent from those of its shareholders, with full control and ownership of all operational assets[121]. - The company has established an independent financial department with a standardized accounting system and separate bank accounts, ensuring no shared accounts with the controlling shareholder[123]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal and regulatory requirements[111]. - The company has implemented a performance evaluation incentive system linking the income of directors and senior management to the company's operational performance[114]. - The company has a robust governance structure, including a general meeting of shareholders, board of directors, and supervisory board, ensuring clear functional roles[124]. - The company actively engages with investors through various platforms to enhance communication and transparency[115]. Employee and Organizational Development - The total number of employees at the end of the reporting period is 537, with 158 in the parent company and 379 in major subsidiaries[148]. - The professional composition includes 309 production personnel, 15 sales personnel, 119 technical personnel, 14 financial personnel, and 80 administrative personnel[148]. - The company emphasizes employee training, with a structured training system that includes both internal and external training programs[150]. - The company adheres to a strict salary policy, ensuring fair compensation based on job value and individual performance[149]. - The company has a focus on rewarding employees who contribute to technological improvements and management enhancements[149]. Risks and Challenges - The company faces risks related to the implementation of fundraising projects, which may be affected by market conditions and could lead to lower-than-expected investment returns[12]. - The pharmaceutical industry is significantly influenced by national policies, such as medical insurance cost control and drug price reductions, which may impact the company's operations[6]. - The company has faced increasing challenges in the pharmaceutical industry due to regulatory and market pressures, necessitating a transformation and upgrade in operations[35]. - The company recognizes the risks associated with fundraising project implementation, including potential market changes and increased fixed asset depreciation impacting profitability[103][104]. Future Outlook - The company plans to enhance marketing capabilities and expand sales channels, focusing on steady growth in the sales of starting materials and hormone intermediates[92]. - The company aims to increase R&D investment in 2023, with a focus on new products and processes, leveraging its R&D centers in Wuhan and Hangzhou[95]. - The company is committed to accelerating project construction to expand production capacity and improve overall profitability, targeting high-end intermediates and active pharmaceutical ingredients[96]. - The company provided a revenue guidance of $500 million for the next fiscal year, representing a 20% increase[181]. - Future outlook remains positive, with an anticipated growth rate of 12% over the next three years[181].

| 证券代码：300966 | 证券简称：共同药业 公告编号：2023-026 | | --- | --- | | 转债代码：123171 | 转债简称：共同转债 | 湖北共同药业股份有限公司 关于举办2022年年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 投 资 者 可 于 2023 年 4 月 28 日 （ 星 期 五 ） 15:30-17:00 通过网址 https://eseb.cn/140NcrdtcUU 或者使用微信扫一扫以下小程序即可进入参与互动交流。 投资者可于 2023 年 4 月 28 日前进行会前提问，公司将通过本次业绩说明会，在信 息披露允许范围内就投资者普遍关注的问题进行回答。欢迎广大投资者积极参与！ 为使投资者更全面地了解公司 2022 年年度报告的内容，公司定于 2023 年 4 月 28 日（星期五）15:30-17:00 在"价值在线"（www.ir-online.cn）举办 2022 年年度网 上业绩说明会，与投资者进行交流和沟通，广泛听取投资者的意见和建议。 一、本次说明会召开的时间、地点和方式 ...

编号：2022-02 证券代码：300966 证券简称：共同药业 湖北共同药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------|---------------------------------------------------------------------| | | | | | | 特定对象调研 | 分析师会议 | | | 媒体采访 | 业绩说明会 | | 投资者关系 活动类别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | | 其他（投资者网上集体接待活动暨 2021 年度业绩说明会） | | 形式 | 现场 网上 | 电话会议 | | 参与单位名称 及人员姓名 | 参与公司" 2022 会"的投资者 | 年湖北辖区上市公司投资者集体接待日暨 2021 年度业绩说明 | | 时间 | 2022年6月16日 | 13:30-16:00 | | | 地点 全景网"投 ...

Financial Performance - The company's revenue for Q3 2022 was CNY 178,476,491.30, representing a 24.57% increase compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was CNY 12,936,789.86, a slight decrease of 0.65% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 10,750,661.54, which increased by 14.09% compared to the previous year[5]. - Total operating revenue for the third quarter of 2022 was CNY 446,823,862.70, a slight increase of 0.2% compared to CNY 445,950,409.88 in the same period last year[20]. - Net profit for the third quarter was CNY 39,380,724.76, a decrease of 26.8% compared to CNY 53,826,600.73 in the previous year[21]. - Earnings per share (EPS) for the third quarter was CNY 0.35, down from CNY 0.53 in the same quarter last year[22]. Assets and Liabilities - The total assets at the end of Q3 2022 reached CNY 1,700,933,945.13, marking a 40.43% increase from the end of the previous year[5]. - The company's total liabilities increased to CNY 816,415,663.55, up from CNY 382,828,054.54 year-on-year[21]. - Total equity attributable to shareholders reached CNY 831,292,801.39, compared to CNY 807,053,017.36 in the previous year[21]. - Current assets total CNY 978,088,008.47, up from CNY 858,256,693.11 at the start of the year[18]. - The company's total assets as of September 30, 2022, amount to CNY 1,700,933,945.13, an increase from CNY 1,211,243,283.36 at the beginning of the year[18]. Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 162,678.90, a significant decline of 86.74% compared to the previous year[5]. - Cash flow from operating activities totaled CNY 430,847,358.70, an increase from CNY 380,599,617.66 year-on-year[23]. - The net cash flow from operating activities was 162,678.90, a decrease of 86.8% compared to 1,227,234.45 in the previous period[24]. - Cash inflow from financing activities amounted to 588,484,292.91, up from 353,452,670.00, reflecting a 66.5% increase[24]. - The net cash flow from financing activities increased by 120.67% to CNY 392,968,457.22, attributed to increased investment funds and bank loans[13]. Investments and Expenses - The company reported a 128.61% increase in short-term borrowings, totaling CNY 327,858,000.00, primarily due to the funding needs of a newly established R&D center[9]. - The company’s long-term equity investments increased by 232.62% to CNY 48,135,611.11, reflecting increased investments in joint ventures[9]. - Research and development expenses rose to CNY 29,530,625.12, compared to CNY 24,512,055.83 in the previous year, reflecting a focus on innovation[21]. - The company reported a significant increase in interest expenses, which rose to CNY 9,113,287.89 from CNY 5,269,442.07 year-on-year[21]. Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 13,448[15]. - The largest shareholder, Xi Zubin, holds 31.72% of shares, totaling 36,567,000 shares[15]. - The number of shares held by the top ten unrestricted shareholders includes 5,467,200 shares held by Anhui Lichang Investment Center[16]. - The company has a total of 4,270,700 shares held by Zhejiang Huahai Pharmaceutical Co., Ltd.[16].